39960-05-9

Basic information

• Product Name: 3,4-dichlorobenzenepropanol
• Synonyms: 3,4-dichlorobenzenepropanol
• CAS NO: 39960-05-9
• Molecular Weight: 205.084
• Mol File: 39960-05-9.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 3,4-dichlorobenzenepropanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dichlorobenzenepropanol(39960-05-9)
• EPA Substance Registry System: 3,4-dichlorobenzenepropanol(39960-05-9)

Safety Data

• Hazardous Substances Data: 39960-05-9(Hazardous Substances Data)

Upstream product

• 25173-68-6 3(3,4-dichlorophenyl)propanoic acid 
• 7312-27-8 3,4-Dichlorocinnamic acid 
• 220707-94-8 3-(3,4-dichlorophenyl)prop-2-yn-1-ol 
• 7116-47-4 ethyl 3-(3,4-dichlorophenyl)propanoate 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Downstream Products

• 29648-26-8 1-bromo-3-(3,4-dichlorophenyl)-propane 
• 1258879-09-2 N-[3-(3,4-dichlorophenyl)propyl]-N-hydroxyformamide 
• 1429291-98-4 N-(4-(3,4-dichlorophenyl)butan-2-yl)-1-ethyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide 
• 1610455-13-4 1,2-dichloro-4-isocyanato-5-(3-methoxypropyl)benzene 
• 1610455-09-8 4,5-dichloro-2-(3-methoxypropyl)aniline 
• 1610455-11-2 1,2-dichloro-4-(3-methoxypropyl)-5-nitrobenzene 
• 1610454-95-9 tert-butyl 4-(2-((5-(3-(4,5-dichloro-2-(3-methoxypropyl)phenyl)ureido)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)ethyl)piperazine-1-carboxylate 
• 1610454-84-6 (S)-1-(4,5-dichloro-2-(3-methoxypropyl)phenyl)-3-(4-methyl-3-(morpholin-2-ylmethoxy)-1-phenyl-1H-pyrazol-5-yl)urea hydrochloride 
• 1610455-38-3 (S)-tert-butyl 2-(((5-(3-(4,5-dichloro-2-(3-methoxypropyl)phenyl)ureido)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)methyl)morpholine-4-carboxylate 
• 1610454-70-0 1-(4,5-dichloro-2-(3-methoxypropyl)phenyl)-3-(4-methyl-3-((1-methylpiperidin-4-yl)methoxy)-1-phenyl-1H-pyrazol-5-yl)urea 
• 1610454-67-5 (R)-1-(4,5-dichloro-2-(3-methoxypropyl)phenyl)-3-(3-(2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea 
• 1610455-35-0 (S)-1-(4,5-dichloro-2-(3-methoxypropyl)phenyl)-3-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea 
• 1610454-64-2 1-(4,5-dichloro-2-(3-methoxypropyl)phenyl)-3-(4-methyl-3-(1-methylpiperidin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea 
• 1610454-62-0 5-(3-(4,5-dichloro-2-(3-methoxypropyl)phenyl)ureido)-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide 

Relevant articles and documents

NURR1 RECEPTOR MODULATORS

Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models

Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HDAC6-selective inhibitor containing the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker. A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination observed for HDAC6 complexes with phenylhydroxamate-based inhibitors. While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model. These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.

SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS

Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.